RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells

eLife

Volumn 3, Issue November, 2014, Pages 1-23

  van Bragt, Maaike P A ^a,b   Hu, Xin ^a,b,c   Xie, Ying ^a,b   Li, Zhe ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTEGRIN; BETA3 INTEGRIN; CD24 ANTIGEN; ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; PROTEIN P53; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR RUNX1; CITED1 PROTEIN, MOUSE; CRE RECOMBINASE; DNA BINDING PROTEIN; ELF5 PROTEIN, MOUSE; FOXA1 PROTEIN, MOUSE; INTEGRASE; NUCLEAR PROTEIN; RETINOBLASTOMA PROTEIN; RUNX1 PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR;

ADULT; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CARCINOGENESIS; CELL PROLIFERATION; CELL SELECTION; ELF5 GENE; FEMALE; FLOW CYTOMETRY; GENE; GENE DISRUPTION; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENE TARGETING; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN MICROARRAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; AGING; AMINO ACID SEQUENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; DEFICIENCY; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULAR GENETICS; MOUSE MAMMARY TUMOR VIRUS; PATHOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; UDDER;

MOUSE MAMMARY TUMOR VIRUS; MURINAE;

AGING; AMINO ACID SEQUENCE; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA-BINDING PROTEINS; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; INTEGRASES; MAMMARY GLANDS, ANIMAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; RECEPTORS, ESTROGEN; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84922157157     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.03881     Document Type: Article

References (65)

1. Asselin-Labat ML, Sutherland KD, Barker H, Thomas R, Shackleton M, Forrest NC, Hartley L, Robb L, Grosveld FG, van der Wees J, Lindeman GJ, Visvader JE. 2007. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nature Cell Biology 9:201-209. doi: 10.1038/ncb1530.
2. Asselin-Labat ML, Sutherland KD, Vaillant F, Gyorki DE, Wu D, Holroyd S, Breslin K, Ward T, Shi W, Bath ML, Deb S, Fox SB, Smyth GK, Lindeman GJ, Visvader JE. 2011. Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14. Molecular and Cellular Biology 31:4609-4622. doi: 10.1128/MCB.05766-11.
3. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE. 2010. Control of mammary stem cell function by steroid hormone signalling. Nature 465:798-802. doi: 10.1038/nature09027.
4. Banerji S, Cibulskis K, Rangel-Escareno C, Brown KK, Carter SL, Frederick AM, Lawrence MS, Sivachenko AY, Sougnez C, Zou L, Cortes ML, Fernandez-Lopez JC, Peng S, Ardlie KG, Auclair D, Bautista-Piña V, Duke F, Francis J, Jung J, Maffuz-Aziz A, Onofrio RC, Parkin M, Pho NH, Quintanar-Jurado V, Ramos AH, Rebollar-Vega R, Rodriguez-Cuevas S, Romero-Cordoba SL, Schumacher SE, Stransky N, Thompson KM, Uribe-Figueroa L, Baselga J, Beroukhim R, Polyak K, Sgroi DC, Richardson AL, Jimenez-Sanchez G, Lander ES, Gabriel SB, Garraway LA, Golub TR, Melendez-Zajgla J, Toker A, Getz G, Hidalgo-Miranda A, Meyerson M. 2012. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486:405-409. doi: 10.1038/nature11154.
5. Bernardo GM, Lozada KL, Miedler JD, Harburg G, Hewitt SC, Mosley JD, Godwin AK, Korach KS, Visvader JE, Kaestner KH, Abdul-Karim FW, Montano MM, Keri RA. 2010. FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development 137:2045-2054. doi: 10.1242/dev.043299.
6. Best SA, Hutt KJ, Fu NY, Vaillant F, Liew SH, Hartley L, Scott CL, Lindeman GJ, Visvader JE. 2014. Dual roles for Id4 in the regulation of estrogen signaling in the mammary gland and ovary. Development 141:3159-3164. doi: 10.1242/dev.108498.
7. Bravo J, Li Z, Speck NA, Warren AJ. 2001. The leukemia-associated AML1 (Runx1)-CBF beta complex functions as a DNA-induced molecular clamp. Nature Structural Biology 8:371-378. doi: 10.1038/86264.
8. Cancer Genome Atlas Network. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490:61-70. doi: 10.1038/nature11453.
9. Chakrabarti R, Hwang J, Andres Blanco M, Wei Y, Lukacisin M, Romano RA, Smalley K, Liu S, Yang Q, Ibrahim T, Mercatali L, Amadori D, Haffty BG, Sinha S, Kang Y. 2012. Elf5 inhibits the epithelial-mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nature Cell Biology 14:1212-1222. doi: 10.1038/ncb2607.
10. Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, Borok Z, Frenkel B. 2011. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Research 13:R127. doi: 10.1186/bcr3073.
11. Chimge NO, Baniwal SK, Luo J, Coetzee S, Khalid O, Berman BP, Tripathy D, Ellis MJ, Frenkel B. 2012. Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clinical Cancer Research 18:901-911. doi: 10.1158/ 1078-0432.CCR-11-1530.
12. Chimge NO, Frenkel B. 2013. The RUNX family in breast cancer: relationships with estrogen signaling. Oncogene 32:2121-2130. doi: 10.1038/onc.2012.328.
13. Choi YS, Chakrabarti R, Escamilla-Hernandez R, Sinha S. 2009. Elf5 conditional knockout mice reveal its role as a master regulator in mammary alveolar development: failure of Stat5 activation and functional differentiation in the absence of Elf5. Developmental Biology 329:227-241. doi: 10.1016/j.ydbio.2009.02.032.
14. Chuang LS, Ito K, Ito Y. 2013. RUNX family: regulation and diversification of roles through interacting proteins. International Journal of Cancer Journal International Du Cancer 132:1260-1271. doi: 10.1002/ijc.27964.
15. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, De Schryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER. 2012. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486:353-360. doi: 10.1038/nature11143.
16. Ferrari N, Mohammed ZM, Nixon C, Mason SM, Mallon E, McMillan DC, Morris JS, Cameron ER, Edwards J, Blyth K. 2014. Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer. PLOS ONE 9:e100759. doi: 10.1371/journal.pone.0100759.
17. Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, Itzkovitz S, Noske A, Zürrer-Härdi U, Bell G, Tam WL, Mani SA, van Oudenaarden A, Weinberg RA. 2012. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 148:1015-1028. doi: 10.1016/j.cell.2012.02.008.
18. Haaksma CJ, Schwartz RJ, Tomasek JJ. 2011. Myoepithelial cell contraction and milk ejection are impaired in mammary glands of mice lacking smooth muscle alpha-actin. Biology of Reproduction 85:13-21. doi: 10.1095/ biolreprod.110.090639.
19. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA. 2013. Super-enhancers in the control of cell identity and disease. Cell 155:934-947. doi: 10.1016/j.cell.2013.09.053.
20. Howlin J, McBryan J, Napoletano S, Lambe T, McArdle E, Shioda T, Martin F. 2006. CITED1 homozygous null mice display aberrant pubertal mammary ductal morphogenesis. Oncogene 25:1532-1542. doi: 10.1038/sj.onc.1209183.
21. Huang B, Qu Z, Ong CW, Tsang YH, Xiao G, Shapiro D, Salto-Tellez M, Ito K, Ito Y, Chen LF. 2012. RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor alpha. Oncogene 31:527-534. doi: 10.1038/onc.2011.252.
22. Huang S, Guo YP, May G, Enver T. 2007. Bifurcation dynamics in lineage-commitment in bipotent progenitor cells. Developmental Biology 305:695-713. doi: 10.1016/j.ydbio.2007.02.036.
23. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS. 2011. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nature Genetics 43:27-33. doi: 10.1038/ng.730.
24. Jones FE, Jerry DJ, Guarino BC, Andrews GC, Stern DF. 1996. Heregulin induces in vivo proliferation and differentiation of mammary epithelium into secretory lobuloalveoli. Cell Growth & Differentiation 7:1031-1038.
25. Kalyuga M, Gallego-Ortega D, Lee HJ, Roden DL, Cowley MJ, Caldon CE, Stone A, Allerdice SL, Valdes-Mora F, Launchbury R, Statham AL, Armstrong N, Alles MC, Young A, Egger A, Au W, Piggin CL, Evans CJ, Ledger A, Brummer T, Oakes SR, Kaplan W, Gee JM, Nicholson RI, Sutherland RL, Swarbrick A, Naylor MJ, Clark SJ, Carroll JS, Ormandy CJ. 2012. ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer. PLOS Biology 10:e1001461. doi: 10.1371/journal.pbio.1001461.
26. Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S, Smith AE, Prat A, Perou CM, Gilmore H, Schnitt S, Naber SP, Garlick JA, Kuperwasser C. 2012. Defining the cellular precursors to human breast cancer. Proceedings of the National Academy of Sciences of USA 109:2772-2777. doi: 10.1073/pnas.1017626108.
27. Kouros-Mehr H, Slorach EM, Sternlicht MD, Werb Z. 2006. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127:1041-1055. doi: 10.1016/j.cell.2006.09.048.
28. Li S, Chang S, Qi X, Richardson JA, Olson EN. 2006a. Requirement of a myocardin-related transcription factor for development of mammary myoepithelial cells. Molecular and Cellular Biology 26:5797-5808. doi: 10.1128/ MCB.00211-06.
29. Li W, Ferguson BJ, Khaled WT, Tevendale M, Stingl J, Poli V, Rich T, Salomoni P, Watson CJ. 2009. PML depletion disrupts normal mammary gland development and skews the composition of the mammary luminal cell progenitor pool. Proceedings of the National Academy of Sciences of USA 106:4725-4730. doi: 10.1073/ pnas.0807640106.
30. Li Z, Chen MJ, Stacy T, Speck NA. 2006b. Runx1 function in hematopoiesis is required in cells that express Tek. Blood 107:106-110. doi: 10.1182/blood-2005-05-1955.
31. Li Z, Yan J, Matheny CJ, Corpora T, Bravo J, Warren AJ, Bushweller JH, Speck NA. 2003. Energetic contribution of residues in the Runx1 Runt domain to DNA binding. The Journal of Biological Chemistry 278:33088-33096. doi: 10.1074/jbc.M303973200.
32. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, k Con Fab, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ. 2009. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine 15:907-913. doi: 10.1038/nm.2000.
33. Lim E, Wu D, Pal B, Bouras T, Asselin-Labat ML, Vaillant F, Yagita H, Lindeman GJ, Smyth GK, Visvader JE. 2010. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Research 12:R21. doi: 10.1186/bcr2560.
34. Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA. 2013. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153:320-334. doi: 10.1016/j.cell.2013.03.036.
35. Meier-Abt F, Milani E, Roloff T, Brinkhaus H, Duss S, Meyer DS, Klebba I, Balwierz PJ, van Nimwegen E, Bentires-Alj M. 2013. Parity induces differentiation and reduces Wnt/Notch signaling ratio and proliferation potential of basal stem/progenitor cells isolated from mouse mammary epithelium. Breast Cancer Research 15:R36. doi: 10.1186/bcr3419.
36. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A, Reis-Filho JS, Smalley MJ. 2010. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7:403-417. doi: 10.1016/j.stem.2010.07.010.
37. Oakes SR, Naylor MJ, Asselin-Labat ML, Blazek KD, Gardiner-Garden M, Hilton HN, Kazlauskas M, Pritchard MA, Chodosh LA, Pfeffer PL, Lindeman GJ, Visvader JE, Ormandy CJ. 2008. The Ets transcription factor Elf5 specifies mammary alveolar cell fate. Genes & Development 22:581-586. doi: 10.1101/gad.1614608.
38. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. 1996. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321-330. doi: 10.1016/S0092-8674(00)80986-1.
39. Phillips S, Prat A, Sedic M, Proia T, Wronski A, Mazumdar S, Skibinski A, Shirley SH, Perou CM, Gill G, Gupta PB, Kuperwasser C. 2014. Cell-State transitions regulated by SLUG are critical for tissue regeneration and tumor initiation. Stem Cell Reports 2:633-647. doi: 10.1016/j.stemcr.2014.03.008.
40. Plante I, Wallis A, Shao Q, Laird DW. 2010. Milk secretion and ejection are impaired in the mammary gland of mice harboring a Cx43 mutant while expression and localization of tight and adherens junction proteins remain unchanged. Biology of Reproduction 82:837-847. doi: 10.1095/biolreprod.109.081406.
41. Preudhomme C, Renneville A, Bourdon V, Philippe N, Roche-Lestienne C, Boissel N, Dhedin N, Andre JM, Cornillet-Lefebvre P, Baruchel A, Mozziconacci MJ, Sobol H. 2009. High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder. Blood 113:5583-5587. doi: 10.1182/ blood-2008-07-168260.
42. Proia TA, Keller PJ, Gupta PB, Klebba I, Jones AD, Sedic M, Gilmore H, Tung N, Naber SP, Schnitt S, Lander ES, Kuperwasser C. 2011. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell 8:149-163. doi: 10.1016/j.stem.2010.12.007.
43. Ramaswamy S, Ross KN, Lander ES, Golub TR. 2003. A molecular signature of metastasis in primary solid tumors. Nature Genetics 33:49-54. doi: 10.1038/ng1060.
44. Rios AC, Fu NY, Lindeman GJ, Visvader JE. 2014. In situ identification of bipotent stem cells in the mammary gland. Nature 506:322-327. doi: 10.1038/nature12948.
45. Schafer JM, Lee ES, O'Regan RM, Yao K, Jordan VC. 2000. Rapid development of tamoxifen-stimulated mutant p53 breast tumors (T47D) in athymic mice. Clinical Cancer Research 6:4373-4380.
46. Scheitz CJ, Tumbar T. 2013. New insights into the role of Runx1 in epithelial stem cell biology and pathology. Journal of Cellular Biochemistry 114:985-993. doi: 10.1002/jcb.24453.
47. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ, Visvader JE. 2006. Generation of a functional mammary gland from a single stem cell. Nature 439:84-88. doi: 10.1038/ nature04372.
48. Shehata M, Teschendorff A, Sharp G, Novcic N, Russell A, Avril S, Prater M, Eirew P, Caldas C, Watson CJ, Stingl J. 2012. Phenotypic and functional characterization of the luminal cell hierarchy of the mammary gland. Breast Cancer Research 14:R134. doi: 10.1186/bcr3334.
49. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, Loh M, Felix C, Roy DC, Busque L, Kurnit D, Willman C, Gewirtz AM, Speck NA, Bushweller JH, Li FP, Gardiner K, Poncz M, Maris JM, Gilliland DG. 1999. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nature Genetics 23:166-175. doi: 10.1038/13793.
50. Speck NA, Gilliland DG. 2002. Core-binding factors in haematopoiesis and leukaemia. Nature Reviews Cancer 2:502-513. doi: 10.1038/nrc840.
51. Spike BT, Engle DD, Lin JC, Cheung SK, La J, Wahl GM. 2012. A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer. Cell Stem Cell 10:183-197. doi: 10.1016/j.stem.2011.12.018.
52. Stender JD, Kim K, Charn TH, Komm B, Chang KC, Kraus WL, Benner C, Glass CK, Katzenellenbogen BS. 2010. Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Molecular and Cellular Biology 30:3943-3955. doi: 10.1128/MCB.00118-10.
53. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ. 2006. Purification and unique properties of mammary epithelial stem cells. Nature 439:993-997.
54. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. 2005. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of USA 102:15545-15550. doi: 10.1073/pnas.0506580102.
55. Tahirov TH, Inoue-Bungo T, Morii H, Fujikawa A, Sasaki M, Kimura K, Shiina M, Sato K, Kumasaka T, Yamamoto M, Ishii S, Ogata K. 2001. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta. Cell 104:755-767. doi: 10.1016/S0092-8674(01)00271-9.
56. Taniuchi I, Osato M, Ito Y. 2012. Runx1: no longer just for leukemia. The EMBO Journal 31:4098-4099. doi: 10.1038/emboj.2012.282.
57. Tao L, van Bragt MPA, Laudadio E, Li Z. 2014. Lineage tracing of mammary epithelial cells using cell-type-specific cre-expressing adenoviruses. Stem Cell Reports 2:770-779. doi: 10.1016/j.stemcr.2014.04.004.
58. van Amerongen R, Bowman AN, Nusse R. 2012. Developmental stage and time dictate the fate of Wnt/ beta-catenin-responsive stem cells in the mammary gland. Cell Stem Cell 11:387-400. doi: 10.1016/j. stem.2012.05.023.
59. Van Keymeulen A, Rocha AS, Ousset M, Beck B, Bouvencourt G, Rock J, Sharma N, Dekoninck S, Blanpain C. 2011. Distinct stem cells contribute to mammary gland development and maintenance. Nature 479:189-193. doi: 10.1038/nature10573.
60. Wagner KU, Wall RJ, St-Onge L, Gruss P, Wynshaw-Boris A, Garrett L, Li M, Furth PA, Hennighausen L. 1997. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Research 25:4323-4330. doi: 10.1093/ nar/25.21.4323.
61. Walkley CR, Qudsi R, Sankaran VG, Perry JA, Gostissa M, Roth SI, Rodda SJ, Snay E, Dunning P, Fahey FH, Alt FW, McMahon AP, Orkin SH. 2008. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes & Development 22:1662-1676. doi: 10.1101/gad.1656808.
62. Wang D, Cai C, Dong X, Yu QC, Zhang XO, Yang L, Zeng YA. 2014. Identification of multipotent mammary stem cells by protein C receptor expression. Nature. doi: 10.1038/nature13851.
63. Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH, Speck NA. 1996. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proceedings of the National Academy of Sciences of USA 93:3444-3449. doi: 10.1073/pnas.93.8.3444.
64. Weymouth N, Shi Z, Rockey DC. 2012. Smooth muscle alpha actin is specifically required for the maintenance of lactation. Developmental Biology 363:1-14. doi: 10.1016/j.ydbio.2011.11.002.
65. Yahata T, Shao W, Endoh H, Hur J, Coser KR, Sun H, Ueda Y, Kato S, Isselbacher KJ, Brown M, Shioda T. 2001. Selective coactivation of estrogen-dependent transcription by CITED1 CBP/p300-binding protein. Genes & Development 15:2598-2612. doi: 10.1101/gad.906301.